Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Julphar
Mallinckrodt
UBS
QuintilesIMS
Express Scripts
Daiichi Sankyo
Citi
Colorcon

Generated: April 20, 2018

DrugPatentWatch Database Preview

AXERT Drug Profile

« Back to Dashboard

When do Axert patents expire, and when can generic versions of Axert launch?

Axert is a drug marketed by Janssen Pharms and is included in one NDA.

The generic ingredient in AXERT is almotriptan malate. There are six drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the almotriptan malate profile page.
Summary for AXERT
Drug patent expirations by year for AXERT
Synonyms for AXERT
(zznon-labelled)Almotriptan-d6 Malate
1-(((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)sulfonyl)pyrrolidine hydroxybutanedioate
1-(((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)sulfonyl)pyrrolidine, hydroxybutanedioate (1:1)
1-(((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)sulfonyl)pyrrolidine, hydroxybutanedionate (1:1)
1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine malate
1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine malate (1:1)
1-[[[2-(Dimethyl-amino)ethyl]-1H-indol-5-yl]methyl]sulfonyl]pyrrolidine Malate
1-[[[3-(2-dimethylamino)ethyl]-1H-indol-5-yl]-methyl]sulfonyl]pyrrolidine (+/-)-hydroxybutanedioate
1-[[3-(2-dimethylaminoethyl)-5-indolyl]methanesulphonyl]pyrrolidine Malate
181183-52-8
3-[2-(Dimethylamino)ethyl]-5-(pyrrolidin-1-ylsulfonylmethyl )-1H-indole malate
AB0011374
AB1004826
AC1L3WYS
AK110510
AKOS015950790
Almotriptan (malate)
Almotriptan malate
Almotriptan malate (Axert)
Almotriptan malate (USAN)
Almotriptan malate [USAN]
Almotriptan Malate(PNU180638)
Almotriptan MalateSee: A575201
Almotriptan maleate
ALMOTRIPTAN; MALIC ACID
AN-16757
API0000367
AS-12142
AX8113232
Axert (TN)
BCP9000276
Butanedioic acid, hydroxy-, compd. with 1-(((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)sulfonyl)pyrrolidine (1:1)
C21H31N3O7S
CHEBI:53781
CHEMBL1200521
CS-2455
D02825
DTXSID1044225
FT-0661519
HE069626
HE319722
HMS3651A12
HY-B0383
J-011571
KB-47261
KS-00000FM2
LAS 31416
LAS 31416 D,L-malate acid
LAS-31416 D,L-Malate acid
LAS-31416 Malate
LS-181812
MFCD08067740
MLS006010048
MolPort-006-391-878
N,N-dimethyl-2-(5-((pyrrolidin-1-ylsulfonyl)methyl)-1H-indol-3-yl)ethan-1-amine 2-hydroxysuccinate
N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine; 2-hydroxybutanedioic acid
PNU 180638
PNU 180638E
PNU-180638E
QHATUKWEVNMHRY-UHFFFAOYSA-N
s2096
SCHEMBL221131
SMR004701216
SR-05000001986
SR-05000001986-2
ST24045938
VA10091

US Patents and Regulatory Information for AXERT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms AXERT almotriptan malate TABLET;ORAL 021001-001 May 7, 2001 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Janssen Pharms AXERT almotriptan malate TABLET;ORAL 021001-002 May 7, 2001 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for AXERT
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 6.25 mg and 12.5 mg ➤ Subscribe 2005-12-08

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Queensland Health
US Army
Colorcon
Cantor Fitzgerald
Express Scripts
Daiichi Sankyo
Teva
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.